Head & Neck
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "FIREFLY-1 Trial - Type II RAF Inhibitor Tovorafenib in R/R Pediatric Low Grade Glioma"
FEATURING
David Ziegler
- 81 views
- July 11, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Analyses of TTX-080, a First-in-Class HLA-G Antagonist, in Combination With Cetuximab in Patients With mCRC and HNSCC"
FEATURING
Susanna Ulahannan
- 13 views
- July 3, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Petosemtamab With Pembro as 1L Treatment of Recurrent/Metastatic HNSCC"
FEATURING
Cesar Perez
- 57 views
- July 3, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 H&N Highlights: "Key Trial Updates in H&N Cancers"
FEATURING
Nabil Saba
- 732 views
- June 13, 2024
- 4
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Summary: "News in Head&Neck Cancers"
FEATURING
Paolo Bossi
- 345 views
- June 14, 2024
- 8
ecancer
ASCO® 2024 Insights: "E3311 Trial - Enhancing Oropharynx Cancer Outcomes With Transoral Surgery and Deintensified Post-Op Care"
FEATURING
Barbara Burtness
- 32 views
- June 20, 2024
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "Triple Oral Metronomic Therapy + Chemo Regimen vs. Chemo Alone in Advanced Unresectable HNSCC"
FEATURING
Akhil Kapoor
- 69 views
- June 12, 2024
- 2
2024 ASCO® Annual Meeting Insights Hub
ASCO® 2024 Insights: "PRGN-2012, a Novel Gorilla Adenovirus-Based IO, Provides the First Treatment That Leads to Complete & Durable Responses in Recurrent Respiratory Papillomatosis Patients"
FEATURING
Scott Norberg
- 61 views
- June 7, 2024
- 1